Temple Health is testing a tiny, flexible scaffold aimed at relieving a common problem for emphysema patients: overinflation ...

The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...

Add Yahoo as a preferred source to see more of our stories on Google. A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of ...

Phase 2 trial launched for verekitug in COPD, expanding treatment indications for severe respiratory conditions. Top data expected in 2026. Upstream Bio, Inc. has initiated a global Phase 2 clinical ...

WILMINGTON, Del.--(BUSINESS WIRE)--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of ...

Are you finding that your chronic obstructive pulmonary disease (COPD) is making it harder to do the things you enjoy? Canceling plans more often? Missing work due to flare-ups? It could mean your ...

David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

This article supports the use of the chronic obstructive pulmonary disease (COPD) treatment ratio as a surrogate marker of COPD exacerbation risk for quality measurement purposes. Objectives: Despite ...

The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease (COPD), Sanofi and Regeneron announced on Friday. An injectable interleukin ...

Chronic obstructive pulmonary disease (COPD) treatments involving inhaled corticosteroids (ICSs) were associated with a greater risk for fractures, a meta-analysis of several dozen randomized trials ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...